
Brad Loncar's ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars of cancer R&D
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
To prepare for the future, it helps to look back on what has happened in the past. ASCO is a great benchmark for doing that. Drug development does not happen overnight. A pattern of real progress emerges if you view things in the context of two “ASCOs” ago, or five, or ten. I always try to approach it from this macro perspective as I prepare for the conference because it helps set the stage for how today’s new developments might fit in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.